An interventional study of Long term heart rythm monitoring by ECG247 in Atrial Fibrillation (AF), Stroke and NT-pro-BNP, sponsored by University Hospital of North Norway. Recruiting at 2 sites in Norway. Open to participants aged 40 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-15.
Sponsored by University Hospital of North Norway · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies in Atrial Fibrillation with a site in Norway — 8 open to participants now, 13 under way, 1 of them phase 3. Atrial Fibrillation · Norway.
Among the 70 studies in Atrial Fibrillation with a site in Norway, this one is the 15th largest by planned enrollment of the 53 interventional ones that give a count, is the only one that started in 2025, is one of 23 with no phase, reaches primary completion later than 11 of the 12 other live ones, and was the 66th registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →8 of the 70 studies in Atrial Fibrillation with a site in Norway are open now. Recruiting first, the newest first:
Oslo University Hospital · Sites in Norway, United States, Belgium and 7 more countries
Ages 18+
Sorlandet Hospital HF · Sites in Norway
Ages 18+
Vestre Viken Hospital Trust · Sites in Norway
Ages 18+
Sorlandet Hospital HF · Sites in Norway
Ages 18+
Region Stockholm · Sites in Norway, Finland, Iceland and 1 more country
Ages 18+
A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 40 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 4,000 is above the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.
Median enrollment 450 across the 53 interventional studies, 410 across the 17 observational. Of the 54 that completed or were terminated, 20 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 70 have an industry lead sponsor. The 10 most frequent:
University Hospital of North Norway is the lead sponsor of 152 studies on the registry; 24 are open to participants now.
University Hospital of North Norway has 1 study filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 70 studies in Atrial Fibrillation with a site in Norway, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim is to investigate whether screening with long-term ECG monitoring in individuals with elevated NT-proBNP leads to a lower incidence of ischeamic stroke and death from vascular causes. The project is a sub-study within the 8th wave of the population based Tromsø Study. Information on previous diseases, medication use, and risk factors is collected through questionnaires, blood samples, and measurements of height, weight, blood pressure, and ECG.
A total of 4,000 individuals with NT-proBNP levels above the median, without previously known atrial fibrillation (AF) or ongoing anticoagulation therapy, will be randomized to either long-term heart rhythm monitoring (7 days) or a control group without long-term ECG monitoring (2,000 in each group). Individuals with AF in the intervention group will be offered anticoagulation therapy in accordance with current guidelines.
The intervention group and the control group will be compared with regards to incident stroke and death within a 6-year follow-up period. Information on endpoints and anticoagulation use will be obtained through linkage to national registries.
This project has the potential for providing new knowledge related to the benefit of a stepwise screening approach for AF according to NT-proBNP level, utilizing a novel patch monitor with continuous ECG monitoring and automatic artificial intelligence based (AI) ECG analysis. The present project is planned as a sub-study of the epidemiological population-based Tromsø Study. In a randomized controlled clinical trial, we plan to test the primary hypothesis that in individuals with elevated NT-ProBNP who are diagnosed with AF through long-term ECG monitoring, anticoagulation treatment according to international guidelines will reduce the incidence of incident ischeamic stroke and cardiovascular death in the screening group compared to individuals who do not undergo screening (control group). The study will be performed within a well-defined cohort with extensive available longitudinal and cross-sectional information on risk factors and co-existing conditions. This setup facilitates addressing several knowledge gaps concerning risk stratification including associations between AF and echocardiographic parameters, cognitive impairment, structural changes on brain MRI, and HRQoL.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A total of 2000 individuals with NT-proBNP levels above the median, without previously known atrial fibrillation (AF) or ongoing anticoagulation therapy, will be randomized long-term heart rhythm monitoring using ECG247 (5-7 days). Individuals with AF in the intervention group will be offered anticoagulation therapy in accordance with current guidelines.
Diagnostic Test: Long term heart rythm monitoring by ECG247
The control arm
The AF screening device will be sent by post from the study centre to participants in the intervention group at inclusion, free-of-charge. User guides and a "help-desk" located at the University Hospital of North Norway will be available for phone/video assistance. Continuous ECG monitoring using the Norwegian produced ECG247 sensor will be performed for 5-7 days. Single lead ECG data is sent to a cloudbased server intermittently. The system stores information of ECG quality and is evaluated by trained algorithms which classify arrhythmias based on current criteria. All ECG recordings will be reviewed by a group of trained and experienced study nurses and physicians. In the event of clinically relevant arrhythmias, participants will be contacted as soon as possible and receive advice on follow-up with their general practitioner. Anticoagulation therapy and other treatments will be recommended if indicated according to current guidelines.
Number of participants with the composite outcome of ischemic stroke or cardiovascular death
Composite outcome of ischemic stroke and cardiovascular death
Time frame: Within 6 years of screening
Number of participants with ischemic stroke
Ischemic stroke outcome
Time frame: Within 6 years of screening
Number of participants with intracerebral hemorrhage
Intracerebral hemorrhage outcome
Time frame: Within 6 years of screening
Number of participants with cardiovascular death
Cardiovascular death outcome
Time frame: Within 6 years of screening
Number of participants with atrial fibrillation
Atrial fibrillation prevalence
Time frame: Within 14 days of screening
Duration of atrial fibrillation in hours
Atrial fibrillation burden
Time frame: Within 14 days of screening
Left atrial volume index
Echocardiographic measure
Time frame: Within 1 year of screening
Left atrial reservoir strain
Echocardiographic measures
Time frame: Within 1 year of screening
Score on the 12-word immediate recall test
Cognitive test performance outcome
Time frame: Within 6 years of screening
Score on the Mini-Mental State Examination (MMS-E)
Cognitive test performance outcome
Time frame: Within 6 years of screening
Score on the digit symbol coding test
Cognitive test performance outcome
Time frame: Within 6 years of screening
Score on the HRQoL EuroQol-5 Dimension (EQ5D)
Health related quality of life (HRQoL) outcome
Time frame: Within one year of screening
Score on the Whiteley Index
Health anxiety outcome
Time frame: Within one year of screening
Global brain volume
Brain MRI measures
Time frame: Within 2.5 years of screening
Segmental brain volume
Brain MRI measures
Time frame: Within 2.5 years of screening
Volume of white matter lesions
Brain MRI measures
Time frame: Within 2.5 years of screening
Number of clinical and subclinical infarcts
Brain MRI measures
Time frame: Within 2.5 years of screening
Number og micro-hemorrhages
Brain MRI measures
Time frame: Within 2.5 years of screening
Plan to share: No
Started Oct 2025 (actual). Primary completion is estimated for Mar 2032, 76 months after the start.
Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 76 months is above that.
Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital of North Norway →